Your search history is turned on.
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CNSX: MBIO MINDBIO THERAPEUTICS SCIENTISTS PRESENT LANDMARK WOMENS HEALTH TRIALS. COMPANY TO RELEASE PHASE 2A DEPRESSION TRIAL SECONDARY DATA THIS MONTH Vancouver, British Columbia 2 May, 2024 MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the Company or MindBio), a clinical stage biopharma company...
Date: May 1, 2024 Jurisdictions: Alberta, British Columbia, Ontario
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3 MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to announce that it has been presenting MindBio to various parties, institutional investment firms ...
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CNSX: MBIO MINDBIO THERAPEUTICS ANNOUNCES LANDMARK WOMENS HEALTH CNS DRUG TRIALS ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in womens health approved for take-home use of MB22001 MB...
Date: April 25, 2024 Jurisdictions: British Columbia
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CNSX: MBIO MINDBIO LANDMARK SLEEP RESEARCH PUBLISHED IN PRESTIGIOUS NATURE PORTFOLIO JOURNAL TRANSLATIONAL PSYCHIATRY MindBio scientists sleep research published in prestigious peer reviewed scientific journal MindBios proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the ...
Date: April 16, 2024 Jurisdictions: Alberta, British Columbia, Ontario
FORM 51102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company MindBio Therapeutics Corp 1055 West Georgia Street,1500 Royal Centre P.O Box 11117 Vancouver, BC V6E 4N7 CANADA Item 2 Date of Material Change April 16, 2024 Item 3 News Release A news release announcing the material change was d...
A Brighter Future for Mental Health CNSX: MBIO Vancouver, British Columbia 16 April, 2024 MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the Company or MindBio) is pleased to announce Riverfort Global Opportunities PCC Ltd has requested to convert CAD$100,000 of its loan to 2,000,000 MindBio shares (Shares) at $0.05 per Share. All Shares wil...
Date: March 20, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CNSX: MBIO MINDBIO BEGINS LANDMARK PHASE 2B TAKE-HOME MICRODOSING (MB22001) CLINICAL TRIAL IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder Follows successful Phase 2A trial where 53% of depressed patients were in complete...
Date: February 26, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CSE: MBIO MINDBIO THERAPEUTICS ANNOUNCES POSITIVE DEPRESSION DATA FROM WORLD-FIRST PHASE 2A TAKE-HOME MICRODOSING TRIAL. OVER HALF OF PATIENTS IN COMPLETE REMISSION AFTER 8 WEEKS OF TAKING MB22001 MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trial ...
Date: February 14, 2024 Jurisdictions: Alberta, British Columbia, Ontario
A Brighter Future for Mental Health CSE: MBIO MINDBIO THERAPEUTICS COMPLETES WORLD FIRST TAKE HOME PHASE 2A MICRODOSING DEPRESSION TRIAL Vancouver, British Columbia February 14, 2024 MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the Company or MindBio), a leading biopharma company in psychiatric medicine development, is delighted to annou...